LYMPHARMA NEWS
Muti-Targeted MEK/PI3K/mTOR Small Molecule "Lymphatropic" Inhibitor LP-182 Receives FDA Orphan-Drug
Lympharma has received approval notice from The Office of the FDA Orphan Drug Products Development in support of Lympharma’s Orphan-Drug Designation application for orphan-drug designation of mitogen-activated protein kinase (MEK) / phosphatidylinositol 3-kinase (PI3K) / mammalian target of rapamycin (mTOR) inhibitor (LP-182) for “treatment of myelofibrosis.”
- Registration # DRU-2023-9820 Orphan-Drug Designation.
Intellectual Property
Intellectual property patents related to key small molecule therapeutics have been approved.
- USA
- Canada
- Australia
- EU
- Japan
- Korea
- China
- additional pending